TPTX » Topics » Net Loss

This excerpt taken from the TPTX 10-Q filed Nov 9, 2006.

Net Loss

          We experienced net losses of $7,090,000 ($1.06 per share-basic and diluted) and $5,687,000 ($0.85 per share-basic and diluted) for the quarters ended September 30, 2006 and 2005, respectively. We experienced net losses of $15,290,000 ($2.28 per share basic and diluted) and $24,299,000 ($3.62 basic and diluted) for the nine months ended September 30, 2006 and 2005, respectively. The decrease in the loss for the nine month period is primarily attributed to business combination costs incurred in 2006 related to the business combination of Axonyx Inc. and TorreyPines Therapeutics, Inc., as discussed in Note 9. These costs are offset in part by a decline in Phenserine program expenditures due to the completion/curtailment of the Phenserine program in late 2005. The increase in the loss for the quarter is attributed to the business combination costs incurred offset in part by a decline in research and development costs.

This excerpt taken from the TPTX 10-Q filed Aug 8, 2006.

Net Loss

                The Company experienced net losses of $4,183,000 ($0.08 per share-basic and diluted) and $8,179,000 ($0.15 per share-basic and diluted) for the quarters ended June 30, 2006 and 2005, respectively. The Company experienced net losses of $8,200,000 ($0.15 per share basic and diluted) and $18,612,000 ($0.35 basic and diluted) for the six months ended June 30, 2006 and 2005, respectively. The decline in loss primarily reflects reduced expenditures in 2006 due to the completion/curtailment of the Phenserine development program in late 2005.

This excerpt taken from the TPTX 10-Q filed May 10, 2006.

Net Loss

The Company experienced net losses of $4,017,000 ($0.07 per share-basic and diluted) and $10,433,000 ($0.19 per share-basic and diluted) for the quarters ended March 31, 2006 and 2005, respectively. The decline in loss primarily reflects reduced expenditures in 2006 due to the completion of the Phenserine development program in late 2005.

 

This excerpt taken from the TPTX 10-Q filed Nov 9, 2005.

Net Loss

The Company experienced net losses of $5,687,000 ($0.11 per share-basic and diluted) and $6,693,000 ($0.13 per share-basic and diluted) for the quarters ended September 30, 2005 and 2004, respectively. The Company experienced net losses of $24,299,000 ($0.45 per share-basic and diluted) and $19,816,000 ($0.40 per share-basic and diluted) for the nine months ended September 30, 2005 and 2004 respectively. The increase in the net loss is primarily due to the expense of the Phase IIB and Phase III clinical trials for Phenserine and initiation of the second and third Phase III clinical trials.

 

This excerpt taken from the TPTX 10-Q filed Aug 8, 2005.

Net Loss

          The Company experienced net losses of $8,179,000 ($0.15 per share-basic and diluted) and $7,132,000 ($0.14 per share-basic and diluted) for the quarters ended June 30, 2005 and 2004, respectively. The Company experienced net losses of $18,612,000 ($0.35 per share-basic and diluted) and $13,123,000 ($0.28 per share-basic and diluted) for the six months ended June 30, 2005 and 2004 respectively. The increase in the net loss is primarily due to the expense of the ongoing Phase IIB and Phase III clinical trials for Phenserine, initiation of the 2nd Phase III clinical trial and an increase in the non-cash stock and option charges.

14



This excerpt taken from the TPTX 10-Q filed May 10, 2005.

Net Loss

                The Company experienced net losses of $10,433,000 ($0.19 per share-basic and diluted) and $5,991,000 ($0.13 per share-basic and diluted) for the quarters ended March 31, 2005 and 2004, respectively. The increase in the net loss is primarily due to the expense of the ongoing Phase IIB and Phase III clinical trials for Phenserine, initiation of the 2nd Phase III clinical trial, an increase in the non-cash stock and option charges and our share of the net loss of OXIS.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki